Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J2VB
|
|||
| Former ID |
DCL000534
|
|||
| Drug Name |
Iboctadekin + rituximab
|
|||
| Synonyms |
Pepstatin A; 26305-03-3; Pepstatine; Ahpatinin C; UNII-V6Y2T27Q1U; MLS002222329; Iva-Val-Val-Sta-Ala-Sta-OH; V6Y2T27Q1U; CHEMBL296588; 39324-30-6; FAXGPCHRFPCXOO-LXTPJMTPSA-N; C34H63N5O9; NCGC00161670-06; Pepstatin (nonspecific); DSSTox_RID_81334; DSSTox_CID_26095; DSSTox_GSID_46095; CCRIS 3603; Pepstatina; Pepstatinum; Pepstatin (VAN); Ia Quinidine
Click to Show/Hide
|
|||
| Drug Type |
Combination drug (Antibody)
|
|||
| Indication | Follicular lymphoma [ICD-11: 2A80] | Phase 1 | [1] | |
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1 | [1] | ||
| Atrial fibrillation [ICD-11: BC81.3; ICD-10: I48] | Investigative | [2] | ||
| Company |
GSK
|
|||
| PubChem Substance ID |
584708, 596110, 826106, 829796, 831223, 835624, 7888351, 7979897, 8030793, 11120284, 11120772, 11121260, 11121685, 11122165, 11362754, 11365316, 11367878, 11370779, 11370780, 11373479, 11376040, 11532940, 11693423, 17397905, 22391554, 26681497, 26717873, 26755331, 26755332, 39469856, 46392467, 46393151, 46394382, 46394420, 46488047, 47216569, 47290927, 47662056, 48034869, 48110235, 49683285, 49699079, 50110894, 50110895, 53790185, 57363881, 76985937, 85148375, 85256984, 85261607
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-18 (IL18) | Target Info | Modulator | [3] |
| Leukocyte surface antigen Leu-16 (CD20) | Target Info | . | [3] | |
| Voltage-gated sodium channel alpha Nav1.9 (SCN11A) | Target Info | Blocker | [2] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NOD-like receptor signaling pathway | ||||
| Cytosolic DNA-sensing pathway | ||||
| Salmonella infection | ||||
| Legionellosis | ||||
| African trypanosomiasis | ||||
| Malaria | ||||
| Tuberculosis | ||||
| Influenza A | ||||
| Inflammatory bowel disease (IBD) | ||||
| Rheumatoid arthritis | ||||
| Hematopoietic cell lineage | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Panther Pathway | Interleukin signaling pathway | |||
| Toll receptor signaling pathway | ||||
| Pathway Interaction Database | IL27-mediated signaling events | |||
| IL12-mediated signaling events | ||||
| IL23-mediated signaling events | ||||
| Cellular roles of Anthrax toxin | ||||
| IL12 signaling mediated by STAT4 | ||||
| Reactome | Interleukin-1 processing | |||
| Interaction between L1 and Ankyrins | ||||
| WikiPathways | Hypertrophy Model | |||
| IL1 and megakaryotyces in obesity | ||||
| Corticotropin-releasing hormone | ||||
| NOD pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | J Clin Oncol 27:15s, 2009 (suppl, abstr 8566). | |||
| REF 2 | New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. | |||
| REF 3 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.